The expression of CTLA-4-specific mRNA was induced in 30% (3/10), 50% (5/10), and 20% (2/10) of CTLA-4-negative hematological cancer cells treated with guadecitabine, DAC or AZA, respectively. Here, CTLA4 is linked to hematopoietic and lymphoid cell neoplasm.